TLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. TLX is selling off hard (regular -6.06%, pre -4.65%, post -1.23%) and is trading below the near-term support zone, with no proprietary buy signals active and no fresh news catalyst this week. Even though analysts are broadly constructive on a medium-term FDA-driven upside case, the current tape is weak and an impatient entry here has poor odds of an immediate payoff.
Trend/price action: Strong near-term bearish momentum (large down day; weakness continued into pre/post market). Momentum: MACD histogram is positive (0.0668) but positively contracting, suggesting upside momentum is fading rather than strengthening. RSI: RSI(6) at 35.79 is near oversold but still classified as neutral here—this can allow a bounce, but it’s not a buy signal by itself. Moving averages: Converging MAs = no clear trend confirmation; combined with the selloff, this points to uncertainty/transition rather than a clean uptrend. Levels: Pivot 7.776. Key supports: S1 7.285 and S2 6.981. Post-market price ~7.20 is below S1, implying a breakdown; next downside reference is S2 ~6.98. Resistances: R1 8.268, R2 8.572. Pattern-based expectation: Similar-pattern stats imply slight negative skew (next day -1.86%, next month -1.41%) with only modest expected upside next week (+1.37%).
Intellectia Proprietary Trading Signals
Analyst-flagged regulatory catalyst: Citi placed TLX on an “upside 90-day catalyst watch,” expecting a re-submission to the FDA for brain imaging agent Pixclara; a successful path could add a meaningful U.S. commercial product. Recent analyst sentiment improved (RBC upgrade to Outperform; Citi reiterates Buy), implying Wall Street sees attractive risk/reward after underperformance.
No news in the past week to support a near-term rebound. Current price action is decisively risk-off (break below S1 support with continued after-hours weakness). Ongoing investor concerns cited by analysts include regulatory approval uncertainty and limited earnings/free-cash-flow growth over the next few years (RBC previously expected broadly flat through FY2027).
Financial snapshot unavailable (data error: “list index out of range”), so latest-quarter growth trends and the latest quarter season cannot be assessed from the provided data.
Recent trend: Ratings have improved at the margin. RBC moved from Sector Perform (initiation) to Outperform (2026-01-19) with the same A$17 target, citing valuation and compelling risk/reward after underperformance. Citi (2026-01-27) maintained Buy with a $22 target and added a 90-day upside catalyst watch tied to a potential FDA re-submission for Pixclara. Wall Street pros: Multiple commercialized diagnostic assets plus pipeline breadth; potential FDA-driven catalyst could unlock meaningful upside. Wall Street cons: Near-/mid-term growth perceived as limited (flat earnings/FCF outlook) and regulatory timelines/approvals remain a key overhang.
